BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hu M, Huang L. Strategies targeting tumor immune and stromal microenvironment and their clinical relevance. Adv Drug Deliv Rev 2022;183:114137. [PMID: 35143893 DOI: 10.1016/j.addr.2022.114137] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Cao Z, Bao Y, Chen Z, Sheng L, Zhou S, Huang Y, Fan J. Fibroblast-epithelial metabolic coupling in laryngeal cancer. Pathology - Research and Practice 2022;240:154177. [DOI: 10.1016/j.prp.2022.154177] [Reference Citation Analysis]
2 Cao Y, Liu S, Ma Y, Ma L, Zu M, Sun J, Dai F, Duan L, Xiao B. Oral Nanomotor-Enabled Mucus Traverse and Tumor Penetration for Targeted Chemo-Sono-Immunotherapy against Colon Cancer. Small 2022;:e2203466. [PMID: 36117129 DOI: 10.1002/smll.202203466] [Reference Citation Analysis]
3 Feng J, Xu L, Zhang S, Geng L, Zhang T, Yu Y, Yuan R, He Y, Nan Z, Lin M, Guo H. A robust CD8+ T cell-related classifier for predicting the prognosis and efficacy of immunotherapy in stage III lung adenocarcinoma. Front Immunol 2022;13:993187. [DOI: 10.3389/fimmu.2022.993187] [Reference Citation Analysis]
4 Wang T, Zhou Z, Wang X, You L, Li W, Zheng C, Zhang J, Wang L, Kong X, Gao Y, Sun X. Comprehensive analysis of nine m7G-related lncRNAs as prognosis factors in tumor immune microenvironment of hepatocellular carcinoma and experimental validation. Front Genet 2022;13:929035. [DOI: 10.3389/fgene.2022.929035] [Reference Citation Analysis]
5 Tian C, Zheng S, Liu X, Kamei KI. Tumor-on-a-chip model for advancement of anti-cancer nano drug delivery system. J Nanobiotechnology 2022;20:338. [PMID: 35858898 DOI: 10.1186/s12951-022-01552-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Ferrari D, Gessi S, Merighi S, Nigro M, Travagli A, Burns JS. Potentiating Cancer Immune Therapy via Nanomaterials and Purinergic Signaling. Front Cell Dev Biol 2022;10:893709. [DOI: 10.3389/fcell.2022.893709] [Reference Citation Analysis]
7 Zhang Y, Chang L, Bao H, Wu X, Liu H, Gou S, Zhang J, Ni J. Constructing New Acid-Activated Anticancer Peptide by Attaching a Desirable Anionic Binding Partner Peptide. J Drug Target 2022;:1-26. [PMID: 35502656 DOI: 10.1080/1061186X.2022.2070627] [Reference Citation Analysis]
8 Zhao YY, Wang MM, Cui JF. New progress in the mechanism of microenvironment-driven chemoradiotherapy resistance in digestive system tumors. Shijie Huaren Xiaohua Zazhi 2022; 30(8): 341-348 [DOI: 10.11569/wcjd.v30.i8.341] [Reference Citation Analysis]